8-K: SeaStar Medical Secures $4.4 Million Through Registered Direct Offering and Private Placement

SeaStar Medical Holding Corporation announced a definitive agreement to issue 4,960,544 shares and warrants in a registered direct offering and concurrent private placement, raising approximately $4.4 million in gross proceeds.

Summary

• SeaStar Medical Holding Corporation entered into a Securities Purchase Agreement with certain institutional investors on July 31, 2025.
• The company sold 4,960,544 shares of its common stock in a registered direct offering.
• Concurrently, the company issued unregistered warrants to purchase up to an aggregate of 4,960,544 shares of common stock in a private placement.
• The combined offering price for each share and accompanying common warrant was $0.887.
• The common warrants have an exercise price of $0.762 per share, are exercisable immediately upon issuance, and will expire five years following the effective date of the resale registration statement.
• H.C. Wainwright & Co., LLC acted as the exclusive placement agent for the offering.
• The company agreed to pay the placement agent a cash fee equal to 7.0% of the aggregate gross proceeds, a management fee equal to 1.0% of gross proceeds, a non-accountable expense allowance of $25,000, reimbursement of up to $50,000 for legal fees and expenses, and a closing fee of $15,950.
• The company also agreed to issue the placement agent warrants to purchase up to 347,238 shares of common stock, with an exercise price of $1.1088 per share, exercisable upon issuance, and expiring on July 31, 2030.
• The gross proceeds from the offering are expected to be approximately $4.4 million.
• The net proceeds from the offering, after deducting fees and expenses (excluding proceeds from warrant exercises), are expected to be approximately $3.9 million.
• The company intends to use the net proceeds for general corporate purposes, including costs and expenses associated with being a public company.
• The offering is expected to close on or about August 1, 2025.
• The company agreed to a 30-day restriction on issuing certain equity securities and a six-month prohibition on variable rate transactions, subject to specific exceptions.
• A holder's right to exercise warrants is limited such that beneficial ownership does not exceed 4.99% or 9.99% (at the holder's election) of outstanding common stock.
• The shares are being offered under an effective shelf registration statement on Form S-3 (File No. 333-275968), effective December 22, 2023.
• The unregistered warrants and underlying shares were issued under Section 4(a)(2) and Rule 506(b) of the Securities Act.
• The company agreed to file a registration statement for the resale of the common warrant shares and placement agent warrant shares within 30 calendar days after July 31, 2025.
• Section 4.12 of prior Securities Purchase Agreements dated June 20, 2025, and July 10, 2025, were amended to permit this transaction and clarify terms regarding at-the-market facilities and the Lincoln Park Purchase Agreement.

Sentiment

Score: 6

Explanation: The filing indicates a successful capital raise which is positive for funding operations and ongoing trials. However, it also involves significant dilution and substantial fees, which are negative for existing shareholders. The company has an FDA-approved product and Breakthrough Device Designations, which are strong positives, but also faces typical biotech risks related to regulatory approval, future funding, and commercialization.

Positives

• Secured approximately $4.4 million in gross proceeds, strengthening the company's financial position.
• Expected net proceeds of approximately $3.9 million are intended for general corporate purposes, including working capital and capital expenditures, supporting ongoing operations.
• The offering was priced 'at-the-market' under Nasdaq rules, indicating a market-aligned valuation for the shares.
• The company's first commercial product, QUELIMMUNE (SCD-PED), was approved by the FDA in 2024 for an ultra-rare condition, providing a revenue stream.
• SCD therapy has received Breakthrough Device Designation for six therapeutic indications from the FDA, potentially accelerating approval and improving reimbursement.
• The company is conducting a pivotal trial for its SCD therapy in adult AKI patients, addressing a significant unmet medical need.

Negatives

• The issuance of 4,960,544 shares and up to 4,960,544 common warrants, plus 347,238 placement agent warrants, will result in significant dilution for existing shareholders upon exercise.
• Substantial fees and expenses are payable to the placement agent, including 7.0% cash fee, 1.0% management fee, $25,000 expense allowance, up to $50,000 for legal fees, and a $15,950 closing fee, reducing net proceeds.
• The company is restricted from issuing certain equity securities for 30 days post-closing and from variable rate transactions for six months, limiting future financing flexibility.
• The common warrant exercise price ($0.762) is below the combined offering price ($0.887), indicating a potential future dilutive event at a lower valuation.
• The Placement Agent Warrants have an exercise price of $1.1088, which is 125% of the offering price, but still represents potential future dilution.

Risks

• Risk that the company may not be able to obtain regulatory approval of its SCD product candidates.
• Risk that the company may not be able to raise sufficient capital to fund its operations, including current or future clinical trials.
• Risk that the company and its current and future collaborators are unable to successfully develop and commercialize its products or services, or experience significant delays in doing so, including failure to achieve approval of its products by applicable federal and state regulators.
• Risk that the company may never achieve or sustain profitability.
• Risk that the company may not be able to secure additional financing on acceptable terms.
• Risk that third-party suppliers and manufacturers are not able to fully and timely meet their obligations.
• Risk of product liability or regulatory lawsuits or proceedings relating to the company's products and services.
• Risk that the company is unable to secure or protect its intellectual property.
• Market and other conditions, and other risks and uncertainties indicated from time to time in the company's Annual Report on Form 10-K, including those under the Risk Factors section therein and in other SEC filings.

Future Outlook

The company intends to use the net proceeds from the offering for general corporate purposes, including costs and expenses associated with being a public company. The offering is expected to close on or about August 1, 2025. The company also plans to file a registration statement for the resale of the Common Warrant Shares and Placement Agent Warrant Shares within 30 calendar days after July 31, 2025, and use commercially reasonable efforts to make it effective within 60 days.

Management Comments

• SeaStar Medical is a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life.
• SeaStar's first commercial product, QUELIMMUNE (SCD-PED), was approved in 2024 by the U.S. Food and Drug Administration (FDA). It is the only FDA approved product for the ultra-rare condition of life-threatening acute kidney injury (AKI) due to sepsis or a septic condition in critically ill pediatric patients.
• SeaStar's Selective Cytopheretic Device (SCD) therapy has been awarded Breakthrough Device Designation for six therapeutic indications by the FDA, enabling the potential for a speedier pathway to approval and preferable reimbursement dynamics at commercial launch.
• The company is currently conducting a pivotal trial of its SCD therapy in adult patients with AKI requiring continuous renal replacement therapy, a life-threatening condition with no effective treatment options that impacts over 200,000 adults in the U.S. annually.

Industry Context

This capital raise by SeaStar Medical, a commercial-stage healthcare company, aligns with the typical financing needs of biotech and medical device firms, especially those with FDA-approved products and ongoing clinical trials. The focus on ultra-rare conditions and Breakthrough Device Designations positions the company in a high-potential, high-risk segment of the healthcare industry, where significant capital is often required to advance products through development and commercialization. The offering helps fund general corporate purposes and public company costs, which is standard for companies at this stage, but also highlights the continuous need for capital in the sector.

Comparison to Industry Standards

• The 'at-the-market' pricing under Nasdaq rules is a common practice for public companies seeking to raise capital efficiently, indicating adherence to standard market mechanisms.
• The 7.0% cash fee and 1.0% management fee for the placement agent are within the typical range for registered direct offerings and private placements in the biotech/healthcare sector, which often see higher fees due to perceived risk and specialized investor targeting.
• The issuance of warrants alongside shares is a common feature in such offerings, often used to sweeten the deal for investors and provide additional upside potential, aligning with industry norms for companies seeking to attract capital.
• The 4.99% / 9.99% beneficial ownership blocker is a standard provision in equity financings to prevent immediate triggering of beneficial ownership reporting requirements (e.g., Schedule 13D) or takeover defenses, common in U.S. public company transactions.
• The 30-day lock-up and 6-month variable rate transaction prohibition are standard protective covenants for investors in such offerings, aiming to prevent immediate dilutive follow-on offerings that could depress the stock price.

Corporate Governance

Stakeholder Impact

• Shareholders: Will experience significant dilution due to the issuance of new shares and warrants. The capital raise provides funding for operations, potentially reducing immediate liquidity concerns, but the lower exercise price of common warrants could further dilute value upon exercise.
• Employees: Continued operations and funding for clinical trials may provide job security and opportunities, as proceeds are for general corporate purposes.
• Customers/Patients: Continued development and potential commercialization of SCD therapy, especially for adult AKI, could lead to new treatment options.
• Creditors: The capital raise improves the company's cash position, potentially enhancing its ability to meet financial obligations.

Next Steps

• Expected closing of the offering on or about August 1, 2025.
• Company to file a registration statement for the resale of Common Warrant Shares and Placement Agent Warrant Shares within 30 calendar days after July 31, 2025.
• Company to use commercially reasonable efforts to cause the resale registration statement to become effective within 60 days following the Closing Date and keep it effective.
• Company to apply to list or quote all of the Shares and Warrant Shares on Nasdaq concurrently with the Closing.
• Company to maintain the listing or quotation of its Common Stock on Nasdaq.
• Company to continue conducting a pivotal trial of its SCD therapy in adult patients with AKI.

Key Dates

Recommendation

The capital raise provides essential funding for SeaStar Medical's operations and ongoing clinical trials, which is a positive for a commercial-stage healthcare company with an FDA-approved product and Breakthrough Device Designations. This reduces immediate liquidity risk. However, the offering involves substantial dilution from the issuance of new shares and warrants, and significant fees to the placement agent. While the company has promising technology in a high-need area (AKI), the dilutive nature of the financing and the inherent risks of clinical development and regulatory approval in the biotech sector suggest a 'hold' position. Investors should monitor the progress of clinical trials, regulatory milestones, and future financing needs, as these will be critical determinants of long-term value.

Keywords

SeaStar Medical, ICU, Registered Direct Offering, Private Placement, Common Stock, Warrants, Capital Raise, Equity Financing, SEC Filing, 8-K, Healthcare Company, Organ Failure, AKI, QUELIMMUNE, SCD Therapy, Breakthrough Device Designation, Nasdaq